Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.03.2021 | Case report

Azacitidine/ivosidenib

Emergence of acquired resistance: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Daigle SR, et al. Molecular characterization of clinical response and relapse inpatients with idh1-mutant newly diagnosed acute myeloidleukemia treated with ivosidenib and azacitidine. Blood 136 (Suppl.): 49-51, 05 Nov 2020. Available from: URL: http://doi.org/10.1182/blood-2020-136922 [abstract] Daigle SR, et al. Molecular characterization of clinical response and relapse inpatients with idh1-mutant newly diagnosed acute myeloidleukemia treated with ivosidenib and azacitidine. Blood 136 (Suppl.): 49-51, 05 Nov 2020. Available from: URL: http://​doi.​org/​10.​1182/​blood-2020-136922 [abstract]
Metadaten
Titel
Azacitidine/ivosidenib
Emergence of acquired resistance: 3 case reports
Publikationsdatum
01.03.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-92645-3

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Lurasidone

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Cyclophosphamide

Case report

Imatinib